<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13087">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659307</url>
  </required_header>
  <id_info>
    <org_study_id>11127DMcA-AS</org_study_id>
    <secondary_id>2012-001589-13</secondary_id>
    <nct_id>NCT01659307</nct_id>
  </id_info>
  <brief_title>The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury</brief_title>
  <acronym>ARENA</acronym>
  <official_title>The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Kingdom Intensive Care Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Ireland Clinical Research Support Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Belfast Health and Social Care Trust</source>
  <oversight_info>
    <authority>United Kingdom: The Belfast Health and Social Care Trust</authority>
    <authority>United Kingdom: Office for Research Ethics Committees Northern Ireland</authority>
    <authority>United Kingdom: Medicine and Healthcare products Regulatory Agency</authority>
    <authority>United Kingdom: Queen's University Belfast</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controled, randomized trial to investigate if aspirin
      pre-treatment has anti-inflammatory effects in a model of acute lung injury induced by
      inhaled endotoxin (LPS) in healthy human volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Bronchoalveolar lavage IL-8 concentration</measure>
    <time_frame>6 hrs after LPS inhalation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alveolar inflammatory response biomarkers</measure>
    <time_frame>6 hrs after LPS inhalation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma inflammatory response biomarkers</measure>
    <time_frame>6 and 24 hrs after LPS inhalation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alveolar epithelial and endothelial function and injury biomarkers</measure>
    <time_frame>6 hrs after LPS inhalation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid inflammatory mediators</measure>
    <time_frame>6 and 24 hrs after LPS inhalation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>Aspirin 75mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 75mg once daily for 7 days. Administered by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Asprin 600mg twice daily for 7 days. Administered by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 7 days. Administered by mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 75mg</intervention_name>
    <description>Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.</description>
    <arm_group_label>Aspirin 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose powder</intervention_name>
    <description>Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.</description>
    <arm_group_label>Lactose powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 1200mg</intervention_name>
    <description>Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.</description>
    <arm_group_label>Aspirin 1200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy non-smoking subjects

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnancy or breast feeding or woman of childbearing potential not using

          -  adequate contraception.

          -  Participation in a clinical trial of an investigational medicinal product within 30
             days

          -  Consent declined Aspirin or non steroidal anti-inflammatory (NSAID) use in the past 4
             weeks

          -  History of asthma

          -  Known aspirin or NSAID hypersensitivity

          -  History of peptic ulcer disease

          -  Platelet count &lt; 150 x 106/ml

          -  Aspirin resistance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny McAuley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University, Belfast</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danny McAuley</last_name>
    <phone>+442890 972144</phone>
    <email>d.f.mcauley@qub.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny McAuley</last_name>
      <phone>+442890 972144</phone>
      <email>d.f.mcauley@qub.a.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>August 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Belfast Health and Social Care Trust</investigator_affiliation>
    <investigator_full_name>Professor Danny McAuley</investigator_full_name>
    <investigator_title>Professor of Intensive care Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute Lung Injury</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Aspirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
